RT Journal Article
T1 The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry
A1 Borque-Fernando, Angel
A1 Rubio-Briones, Jose
A1 Mariano Esteban, Luis
A1 Collado-Serra, Argimiro
A1 Pallas-Costa, Yoni
A1 Angel Lopez-Gonzalez, Pedro
A1 Huguet-Perez, Jorge
A1 Ignacio Sanz-Velez, Jose
A1 Manuel Gil-Fabra, Jesus
A1 Gomez-Gomez, Enrique
A1 Quicios-Dorado, Cristina
A1 Fumado, Lluis
A1 Martinez-Breijo, Sara
A1 Soto-Villalba, Juan
K1 Active surveillance
K1 Prostate cancer
K1 Reclassification
K1 Risk calculator
K1 External validation
AB The follow up of patients on active surveillance requires to repeat prostate biopsies. Predictive models that identify patients at low risk of progression or reclassification are essential to reduce the number of unnecessary biopsies. The aim of this study is to validate the Prostate Active Surveillance Study risk calculator (PASS-RC) in the multicentric Spanish Urological Association Registry of patients on active surveillance (AS), from common clinical practice.Results: We find significant differences in age, PSA and clinical stage between our validation cohort and the PASS-RC generation cohort (p< .0001), with a  reclassification rate of 10–22% on the follow-up Bx, no cancer was found in 43% of the first follow-up Bx. The calibration curve shows underestimation of real appearance of reclassification. The AUC is 0.65 (C.I.95%: 0.60–0.71). PDF and CUC do not suggest a specific cut-off point of clinical use. Methods: We select 498 patients on AS with a minimum of one follow-up biopsy (Bx) from the 1,024 males registered by 36 Spanish centers recruiting patients on the Spanish Urological Association Registry on AS. PASS-RC external validation is carried by means of calibration curve and area under de ROC-curve (AUC), identifyingcut-offs of clinical utility by probability density functions (PDF) and clinical utility curves (CUC). Conclusions: In our first external validation of the PASS-RC we have obtained a moderate discrimination ability, although we cannot recommend cut-off points of clinical use. We suggest the exploration of new biomarkers and/or morpho-functional parameters from multiparametric magnetic resonance image, to improve those necessary tools on AS.
PB Impact Journals LLC
YR 2017
FD 2017-10-03
LK http://hdl.handle.net/10668/19445
UL http://hdl.handle.net/10668/19445
LA en
NO Borque-Fernando Á, Rubio-Briones J, Esteban LM, Collado-Serra A, Pallás-Costa Y, López-González PÁ, et al. The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry. Oncotarget. 2017 Oct 24;8(65):108451-108462
DS RISalud
RD Apr 6, 2025